Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care, Inc. (TNDM) is a company specializing in integrated diabetes management solutions. Today, the stock had a strong bullish movement in the market.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 5.1% on Dec 22, 2025 17:50

• The bullish movement in TNDM stock could be attributed to the recent launch of the t:slim mobile application in Canada, expanding the company's reach and enhancing its integrated diabetes management solutions.
• Despite challenges with a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue, the stock managed to rebound, possibly due to a recent upgrade of Tandem Diabetes Care, reflecting an improved outlook for the company.
• Ongoing investigations by a law firm regarding potential securities claims and class action lawsuits might have initially caused a drop in the stock price, but the market's positive response to the company's product expansion and analyst upgrade helped drive the bullish movement.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem t:slim Mobile App Now Available in Canada

Tandem Diabetes Care, Inc. has launched its t:slim mobile application for Android and iOS users in Canada, expanding its integrated diabetes management solutions. The app allows users to deliver insulin boluses from their smartphone, view real-time pump data, and wirelessly upload information to the cloud-based Tandem Source platform while their t:slim X2 insulin pump continues to function independently. This release aims to bring the benefits of the mobile app to Canadian customers.

https://www.businesswire.com/news/home/20251218516273/en/Tandem-tslim-Mobile-App-Now-Available-in-Canada

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations that the company issued materially misleading business information. This investigation comes after Tandem Diabetes announced a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue that could disrupt insulin delivery, causing the stock to drop significantly. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm regarding participation in a prospective class action for compensation.

https://fox40.com/business/press-releases/cision/20251217DC50212/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation-tndm

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities class action claims against Tandem Diabetes Care, Inc. following a significant stock drop. This investigation comes after the company issued a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could stop insulin delivery. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm to inquire about joining the prospective class action lawsuit.

https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation--tndm-302645167.html

Baird upgrades Tandem Diabetes Care (TNDM)

Baird has upgraded Tandem Diabetes Care (TNDM) in a recent analyst action. This upgrade reflects an improved outlook for the company by Baird analysts.

https://www.msn.com/en-us/money/savingandinvesting/baird-upgrades-tandem-diabetes-care-tndm/ar-AA1St0GK

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. on behalf of investors. This investigation follows a 19.9% stock drop on August 7, 2025, after the company announced a voluntary medical device correction for certain t:slim X2 insulin pumps due to a speaker-related issue that could stop insulin delivery. The firm is preparing a class action lawsuit to recover investor losses.

https://www.wric.com/business/press-releases/cision/20251217DC50212/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation-tndm

Trending Today

Marsh & McLennan Companies Inc. ($MMC) Stock Forecast: Down 0.3% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Nike Inc. ($NKE) Stock Forecast: Up 5.3% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.0% Today

Hologic Inc. ($HOLX) Stock Forecast: Down 0.6% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.3% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 6.1% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.7% Today

Bittensor ($TAO) Crypto Forecast: Down 5.1% Today

Tandem Diabetes Care, Inc. Price History

07.07.2025 - TNDM Stock was down 20.7%

• Tandem Diabetes Care (TNDM) reported a Q2 loss of $0.78, missing the estimated $0.40, leading to a significant drop in the stock price.
• The stock also suffered due to guidance cuts and device recalls, with adverse events and injuries linked to malfunctioning insulin pumps triggering a correction.
• Despite the bearish movement, some analysts are optimistic about TNDM, pointing to technical chart patterns like the formation of a hammer chart and positive revisions in earnings estimates as reasons to consider it a 'buy' opportunity.

07.07.2025 - TNDM Stock was down 28.7%

• TNDM exceeded revenue expectations but reported a loss in Q2, potentially influencing the bearish trend.
• A hammer chart formation and positive adjustments in earnings forecasts from financial analysts hint at a possible turnaround for TNDM, suggesting a chance for investment.
• Investor wariness following the company's recent loss may be contributing to the stock's downward movement.
• Mixed signals from the earnings report and technical chart pattern may be causing uncertainty among investors, leading to TNDM's current downward trajectory.

22.11.2025 - TNDM Stock was up 5.1%

• The bullish movement in TNDM stock could be attributed to the recent launch of the t:slim mobile application in Canada, expanding the company's reach and enhancing its integrated diabetes management solutions.
• Despite challenges with a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue, the stock managed to rebound, possibly due to a recent upgrade of Tandem Diabetes Care, reflecting an improved outlook for the company.
• Ongoing investigations by a law firm regarding potential securities claims and class action lawsuits might have initially caused a drop in the stock price, but the market's positive response to the company's product expansion and analyst upgrade helped drive the bullish movement.

31.09.2025 - TNDM Stock was down 6.9%

• The bearish movement in TNDM's stock today may be linked to the announcement of a securities class action investigation by a law firm. Concerns among investors about potential legal implications possibly triggered a sell-off.
• Despite anticipated outperformance in earnings estimates for the upcoming period, uncertainties related to the investigation might have outweighed any positive outlook, resulting in a negative investor sentiment.
• The current mix of positive earnings expectations and legal concerns has generated a varied sentiment, contributing to a bearish trend for TNDM's stock today.

11.07.2025 - TNDM Stock was down 5.1%

• TNDM stock saw a significant decline after its Q2 earnings announcement, despite surpassing revenue expectations and boosting gross margin. The drop was a result of missed earnings and reduced guidance, leading to a 20% decrease in share price.
• Concerns about device recalls and malfunctions added to the stock's plunge, with a considerable number of adverse incidents and injuries reported. This raised apprehensions among investors regarding the quality and safety standards of the company's products.
• Despite the bearish trend, some experts suggest that TNDM might be approaching a support level, as evidenced by a hammer chart formation. Moreover, the consensus among financial analysts in increasing earnings projections could hint at a buying opportunity for investors interested in the company's long-term potential.

10.09.2025 - TNDM Stock was down 5.2%

• A securities class action investigation could have raised concerns among investors, leading to a sell-off of TNDM shares.
• Investor uncertainty regarding the potential outcomes of the investigation might have contributed to the bearish movement in TNDM stock.
• The negative sentiment surrounding the company due to the ongoing legal scrutiny could have overshadowed any positive developments, impacting the stock price negatively.

04.10.2025 - TNDM Stock was up 5.2%

• The bullish movement in TNDM stock today could be attributed to the anticipation of beating earnings estimates in the upcoming report.
• The news of a securities class action investigation might have initially caused some uncertainty in the market, but investors seem to have focused more on the positive expectations for the earnings report.
• Investors may be optimistic about Tandem Diabetes Care's potential for strong financial performance, leading to increased buying interest and driving the stock price higher.
• Overall, the market movement reflects a mix of short-term concerns regarding the investigation and long-term confidence in the company's earnings potential, resulting in a bullish sentiment for TNDM stock.

16.11.2025 - TNDM Stock was up 6.4%

• The company was upgraded to "Outperform" from "Neutral" by Baird, accompanied by an increased price target. This adjustment signals a favorable outlook on the company's financial future, potentially contributing to the upward movement.
• A previous investigation into a securities class action following a stock decline due to a voluntary medical device correction may have led to initial uncertainty and a decrease in the stock price. However, the subsequent positive outlook and upgrade likely played a role in driving the upward movement.
• While concerns existed regarding pump demand and negative EBITDA, the recent price surge and a possible undervaluation, as indicated by Simply Wall St's DCF model, could have attracted investors, thereby leading to the uptrend.
• In summary, a combination of optimistic analyst assessments, potential undervaluation, and anticipated future growth opportunities probably fueled today's upward movement in Tandem Diabetes Care's stock.

17.08.2025 - TNDM Stock was down 2.7%

• An investigation into potential securities claims on behalf of Tandem Diabetes Care shareholders may have raised concerns and uncertainty among investors, contributing to a bearish movement in the stock.
• An endorsement of Tandem Diabetes Care as a speculative stock for younger investors could have added volatility to the stock, attracting both buyers and sellers and contributing to the bearish trend.
• A contrasting recommendation to buy other stocks like Cintas (NASDAQ: CTAS) and Intuitive Surgical (NASDAQ: ISRG) might have diverted attention and capital away from Tandem Diabetes Care, impacting its stock performance negatively.

20.10.2025 - TNDM Stock was up 5.0%

• Investor optimism regarding TNDM stock is likely due to the recent news of an investigation by the Rosen Law Firm into potential securities claims on behalf of shareholders.
• This development may have boosted investor confidence in the company's outlook.
• The market's reaction suggests that investors are hopeful that any concerns raised in the investigation will be resolved favorably, leading to an increase in the stock price.

01.09.2025 - TNDM Stock was up 7.7%

• Initial uncertainty and bearish sentiment among investors may have been influenced by an ongoing securities fraud investigation.
• If the investigation results do not substantially impact the company, investors may become more confident in Tandem's future prospects, potentially contributing to the bullish movement.
• Market participants seem to view the news positively, indicating that Tandem's financial health and operations may not be significantly impacted by the investigation, resulting in the stock price rise.

10.11.2025 - TNDM Stock was up 6.1%

• The stock of Tandem Diabetes Care (TNDM) experienced a bullish movement following an analyst's target price increase to $23, leading to a 4.5% jump in the stock price.
• Despite the recent gains and analyst optimism, the stock is still down 43.3% year-to-date and trading below its 52-week high, indicating potential room for growth.
• The company's stock rebounded after a previous drop due to a voluntary medical device correction for select t:slim X2 insulin pumps, showcasing resilience in the face of challenges.
• Analysts are re-evaluating Tandem Diabetes Care's valuation, with some intrinsic value estimates below current levels, but competitive pressures and execution challenges pose risks to future growth and margin assumptions.